Newsroom
August 9, 2006
The Commission today announced that it had awarded Urovalve, Inc. of Newark, NJ a $50,000 SBIR Bridge Grant.
The purpose of the SBIR Bridge Grant program is to increase the success and maximize the growth of small New Jersey companies in moving from Phase I to Phase II. The program supports New Jersey’s technology industry by awarding grants to entrepreneurs who have both, applied for Phase II funding and who have been identified as potential Phase II SBIR/STTR awardees. This program will sustain small businesses through the funding gap which occurs between completion of the Phase I grant and the initiation of a Phase II award.
The Commission on Science and Technology strives to increase federal research funding for small technology firms in New Jersey, specifically by increasing investments through the federal Small Business Innovation Research (SBIR) program.
The mission of Urovalve, Inc. is to design, develop, and commercialize superior medical devices that address problems with urinary flow and control. Three specific areas of interest are urinary retention; leakage (incontinence), and diagnostics (urodynamics). The current focus of the Company is on completing development, regulatory approval and commercialization of our initial device; a disposable, patient-controlled intraurethral valved-catheter that is intended to treat chronic male urinary retention (such as that caused by spinal cord injury and neurological diseases) and acute male urinary retention (such as that caused by prostate hypertrophy). Urovalve has developed technology to control fluid flow through small diameter flexible tubing.